IN8bio Showcases Promising Results From INB-100 Therapy Trials
Recently, IN8bio, Inc. (Nasdaq: INAB), a pioneering biopharmaceutical company, presented compelling Phase 1 data regarding its innovative allogeneic gamma-delta T cell therapy, INB-100, at a notable meeting focused on transplantation and cellular therapy. These groundbreaking results highlight the medicine's potential impact on patients grappling with high-risk acute myeloid leukemia (AML). This particular therapy is making waves in the field of hematologic oncology.
Long-Term Remissions and Survival Rates
The data showcased during the presentation reveal that INB-100 is not merely effective but is also capable of delivering long-term remissions. To date, none of the acute myeloid leukemia patients treated with INB-100 have relapsed, with a median follow-up period recorded at 20.1 months. The figures are impressive: a 1-year progression-free survival (PFS) rate of 90.9% and an overall survival (OS) rate of 100% were reported, both of which significantly outstrip historical data sets. Such results indicate that INB-100 is effective, irrespective of patient backgrounds or varying treatment protocols employed by different clinical centers.
Expert Opinions on INB-100
William Ho, the CEO and co-founder of IN8bio, emphasized the importance of these results, stating, "AML patients undergoing allogeneic hematopoietic stem cell transplants commonly encounter high relapse rates due to limited options in post-transplant therapy. The findings surrounding the durability of response and the safety profile of INB-100 could revolutionize the way we manage leukemia post-transplantation." This optimism is echoed by Dr. Michael Bishop, a recognized expert in the field, who pointed out that while advancements have been made in transplantation, relapse remains a critical challenge. His remarks validated the INB-100 findings, which are showing the promise of long-lasting remission without the need for additional maintenance therapy.
Key Phase 1 Insights
The findings highlighted several key points regarding the Phase 1 trials of INB-100:
- Zero Relapses in AML Patients: None of the treated AML patients experienced a relapse, benefiting from over 20 months of median follow-up.
- Exceptional Survival Rates: The therapy achieved a PFS of 90.9% and an OS of 100%.
- Safety Is Paramount: No significant adverse reactions were noted, including cytokine release syndrome, neurotoxicity, or treatment-related fatalities.
- Gamma Delta T Cell Persistence: The therapy displayed evidence of both in vivo expansion and long-term persistence, which may enhance surveillance against any residual leukemia cells.
Addressing the Unmet Need in AML
About 20,000 new cases of AML are diagnosed each year in the U.S., with nearly 11,500 fatalities stemming from the illness. This highlights the critical medical need for more effective therapies. Relapse rates post-HSCT can be as high as 50%, therefore, the introduction of INB-100 aims to fill a significant treatment void by utilizing the natural tumor-fighting characteristics of gamma-delta T cells to drive improved patient outcomes.
Future Prospects for IN8bio
IN8bio is actively working towards accelerating recruitment for its INB-100 program, with expectations to conclude expansion cohort enrollment soon. Encouraging dialogues with the FDA suggest that relapse-free survival may serve as an appropriate primary endpoint for future pivotal trials focused on AML patients.
Webinar Insights and Community Engagement
Recently, IN8bio conducted a Key Opinion Leader webinar which discussed the latest advancements in gamma-delta T cell therapy alongside the promising INB-100 clinical results. This interactive session included expert commentary from Dr. Michael Bishop, providing valuable insights into the ongoing developments.
About IN8bio
IN8bio is committed to developing groundbreaking gamma-delta T cell therapies aimed at addressing cancer treatment challenges. The focus of IN8bio’s primary program, INB-100, is on utilizing haplo-matched allogeneic gamma-delta T cells for AML patients following hematopoietic stem cell transplants. The company is also exploring the application of its proprietary DeltEx DRI gamma-delta T cells in treating glioblastoma, seeking to further expand its therapeutic reach.
Frequently Asked Questions
What is IN8bio’s INB-100 therapy?
INB-100 is an innovative gamma-delta T cell therapy aimed at treating high-risk acute myeloid leukemia (AML) patients, demonstrating significant promise in achieving durable remissions.
What were the results of the Phase 1 trials for INB-100?
The Phase 1 trials reported zero relapses in AML patients at a median follow-up of over 20 months, with impressive survival rates of 90.9% for progression-free survival and 100% for overall survival.
How does INB-100 compare to existing AML treatments?
INB-100 shows potential to outpace traditional options in terms of efficacy and safety, providing much-needed improvements in post-transplant outcomes for AML patients.
Is INB-100 being evaluated in any other cancer types?
Currently, IN8bio is also assessing the application of DeltEx DRI gamma-delta T cells for treating glioblastoma in addition to their work on AML.
What’s next for IN8bio in terms of clinical development?
IN8bio plans to advance the INB-100 program with the expectation of completing recruitment for the expansion cohort soon, anticipating further clinical trials in the future.
